Chief Business Officer
Frederic Allemand, MD, CBO, is an experienced international pharma and biotech marketer and business developer. Frederic 20 year experience ranges from start-up such as Biovector Therapeutics (Toulouse, France) and Hybrigenics (Paris, Fance), etc.) to large publicly-held firms like Bayer (Lewerkusen, Germany) and Syngenta(Basel, Switzerland). Frederic completed more than 50 partnering deals and has an entrepreurship track record as Director of the largest French biotech incubator, Genopole Entreprises (Evry, France), and as cofounder (Medincell, Montpellier, France) or as investor (Surfactis, (Anger, France) in start-up.
Frederic has also been member of the Directorate of Genopole 1er Jour, a pre-seed investment fund and senior advisor for Atlas Venture. Frédéric is currently Chief Business Officer at Biocortech (Paris, France). Frederic was previously Head of Operations and Corporate Development of Phenopro (Illkirch, France), an academic spinout providing research services to biotechnology and pharmaceutical companies that Frederic successfully put on commercial track.
- Agility inside: Agility as a must for biotech start-up to innovate. Biocortech as a case in point (Coming soon)
Among the ingredients required for SMEs to successfully innovate in biotech, corporate agility, defined as the capacity to be timely adaptive and responsive to change is vital. Corporate agility can unfold at tactical or strategical levels. Corporate agility strongly relies - as illustrated by Biocortech case - on timely option building and serendipity.